ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Pengyu Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6904-5499; OpenAlex author ID A5100317572. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper

Papers 1

Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation. Co-author DOI 10.1186/s13046-025-03409-4 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yukuan Feng · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗
Jihui Hao · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗
Lantao Liu · 1 shared paper, 2025 · strength 0.20
- Paper Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochon… DOI 10.1186/s13046-025-03409-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.